EMPAVELI coverage is now available in most provinces

(restrictions may apply)

PrEMPAVELI® (pegcetacoplan) is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor.1

Looking to initiate a patient on EMPAVELI?

Get started by enrolling your patient into the Controlled Distribution Program here or visit EMPAVELI.ca for more information.

Please select a province

See reimbursement information for First Nation and Inuit populations and Canadian veterans2,3.